Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease.

Acute coronary syndrome Antithrombotic treatment Chronic coronary syndrome Coronary artery disease Percutaneous coronary intervention

Journal

European heart journal. Cardiovascular pharmacotherapy
ISSN: 2055-6845
Titre abrégé: Eur Heart J Cardiovasc Pharmacother
Pays: England
ID NLM: 101669491

Informations de publication

Date de publication:
29 07 2023
Historique:
received: 15 03 2023
revised: 15 04 2023
accepted: 27 04 2023
medline: 31 7 2023
pubmed: 30 4 2023
entrez: 30 4 2023
Statut: ppublish

Résumé

Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best antithrombotic strategies in patients with established CAD, classifying each treatment option in relation to the number of antithrombotic drugs irrespective of whether the traditional mechanism of action is expected to mainly inhibit platelets or coagulation cascade. With the aim to reach comprehensiveness of available evidence, we systematically reviewed and performed meta-analyses by means of both direct and indirect comparisons to inform the present consensus document.

Identifiants

pubmed: 37120728
pii: 7147298
doi: 10.1093/ehjcvp/pvad032
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-496

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Marco Valgimigli (M)

Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.
Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland.

Victor Aboyans (V)

Department of Cardiology, Dupuytren University Hospital, and INSERM 1094 & IRD, University of Limoges, 2, Martin Luther King ave, 87042 Limoges, France.

Dominick Angiolillo (D)

Division of Cardiology, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA.

Dan Atar (D)

Department of Cardiology and Institute of Clinical Medicine, Oslo University Hospital Ulleval, University of Oslo, Oslo, Norway.

Davide Capodanno (D)

Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico 'G. Rodolico-San Marco', University of Catania, Via Santa Sofia, 78, Catania 95123, Italy.

Sigrun Halvorsen (S)

Institute of Clinical Medicine, University of Oslo, Blindern, PO Box 1078, N-0316, Oslo, Norway.
Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.

Stefan James (S)

Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala 75185, Sweden.

Peter Jüni (P)

Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Vijay Kunadian (V)

Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Antonio Landi (A)

Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.
Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland.

Sergio Leonardi (S)

University of Pavia and Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Roxana Mehran (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Gilles Montalescot (G)

ACTION Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Eliano Pio Navarese (EP)

Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.

Josef Niebauer (J)

Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.

Angelo Oliva (A)

Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy.

Raffaele Piccolo (R)

Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples Federico II, Naples, Italy.

Susanna Price (S)

Royal Brompton Hospital, National Heart and Lung Institute, Imperial College, London, UK.

Robert F Storey (RF)

Cardiovascular Research Unit, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Heinz Völler (H)

Department of Rehabilitation Medicine, Faculty of Health Science Brandenburg, University of Potsdam, Potsdam, Germany.

Pascal Vranckx (P)

Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Stephan Windecker (S)

Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland.

Keith A A Fox (KAA)

Division of Clinical and Surgical Sciences, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH